Our group is interested in genomic and proteomic analysis of cancer. We apply microarray, mass spectrometry and bioinformatic approaches to discover clinically relevant cancer phenotypes, and identify and validate diagnsotic, predictive and prognostic biomarkers. Our primary focues has been on two diseases, ovarian cancer and sarcoma.
Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA: Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol. 2004 Dec 1;22(23):4700-4710.
Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA, Cannistra SA: Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol. 2005 Nov 1;23(31):7911-8.
Aivado M, Spentzos D, Germing U, Alterovitz G, Meng XY, Grall F, Giagounidis AA, Klement G, Steidl U, Otu HH, Czibere A, Prall WC, Iking-Konert C, Shayne M, Ramoni MF, Gattermann N, Haas R, Mitsiades CS, Fung ET, Libermann TA: Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1307-12.
Spentzos D, Cannistra SA, Grall F, Levine DA, Pillay K, Libermann TA, Mantzoros CS: IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. Endocr Relat Cancer. 2007 Sep;14(3):781-90.
Editorial Board: Journal of Clinical Oncology: 01/08-present
Major Collaborative Activities:
Dr Stephen Cannistra, Dr Towia Libermann, Dr Mark Gebhardt, Dr Jeff Goldsmith, Dr Jonathan Hecht (BIDMC).
Dr John Quackenbush, Dr Aedin Culhane (DFCI).
Dr Dan Cramer, Dr Susan Hankinson, Dr Shelley Tworoger, (BWH).
Dr Edwin Choy (MGH).
